a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

This study tests a CAR-T cell therapy (a treatment where your own immune cells are reprogrammed to attack cancer) for people with multiple myeloma (a plasma cell cancer) or related plasma cell diseases that have returned or are no longer responding to treatment. The therapy targets a protein called BCMA found on myeloma cells. **You may be eligible if...** - You are 18–75 years old with relapsed or refractory multiple myeloma or another plasma cell disease - Your cancer has stopped responding to standard chemotherapy, has relapsed after a bone marrow transplant, or is considered high-risk - Your tumor cells express the BCMA protein - Your heart, liver, lungs, and kidneys are functioning adequately - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have serious mental health disorders - Your heart pumping function (ejection fraction) is below 50% - You have severe organ failure - You have active serious infections Talk to your doctor to see if this trial is right for you.